Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
i-jun.lau@ndorms.ox.ac.uk

I-Jun Lau

Senior Clinical Research Fellow in Translational Myeloma Research

Recent publications

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

Lau I-J. et al, (2026), Blood

Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.

Crump NT. et al, (2021), Cell Rep, 35

H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.

Godfrey L. et al, (2021), Leukemia, 35, 90 - 106

DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation.

Godfrey L. et al, (2019), Nat Commun, 10

PF153 MLL‐AF4 CAUSES ABERRANT UPREGULATION OF PROM1 (CD133) IN ACUTE LYMPHOBLASTIC LEUKEMIA BY CONTROLLING ENHANCER‐PROMOTER INTERACTIONS

Godfrey L. et al, (2019), HemaSphere, 3, 29 - 29

More publications